 |
(S)-10-[(dimethylamino)methyl]-4-ethyl-9hydroxy-4-O-[a-(2″,4″,5″,7″-tetranitro-9″-fluorenylideneaminooxy)propionyl]- 1H-pyrano[3′,4′,6′,7′,] indolizino [1,2-B]-quinoline-3, 14-(4H, 12H)-dione, hydrochloride |
|---|---|
| Trade Name | Lipotecan |
| Orphan Indication | Hepatocellular Carcinoma |
| USA Market Approval | USA |
| USA Designation Date | 2010-10-06 00:00:00 |
| Sponsor | TLC Biopharmaceuticals, Inc.;432 N Canal St, Suite 20;South San Francisco, California, 94080 |
